Should I buy or sell ACADIA Pharmaceuticals stock right now?

15 Wall Street analysts have issued "buy," "hold," and "sell" ratings for ACADIA Pharmaceuticals in the last twelve months. There are currently 3 hold ratings and 12 buy ratings for the stock. The consensus among Wall Street analysts is that investors should "moderate buy" ACAD shares. View ACAD analyst ratings or view top-rated stocks .

What is ACADIA Pharmaceuticals' stock price target for 2024?

15 Wall Street analysts have issued 1 year target prices for ACADIA Pharmaceuticals' stock. Their ACAD share price targets range from $25.00 to $95.00. On average, they anticipate the company's share price to reach $35.82 in the next twelve months. This suggests a possible upside of 109.9% from the stock's current price. View analysts price targets for ACAD or view top-rated stocks among Wall Street analysts .

How have ACAD shares performed in 2024?

ACADIA Pharmaceuticals' stock was trading at $31.31 at the beginning of 2024. Since then, ACAD stock has decreased by 45.5% and is now trading at $17.07. View the best growth stocks for 2024 here .

Are investors shorting ACADIA Pharmaceuticals?

ACADIA Pharmaceuticals saw a increase in short interest in March. As of March 31st, there was short interest totaling 11,200,000 shares, an increase of 5.4% from the March 15th total of 10,630,000 shares. Based on an average daily volume of 1,830,000 shares, the days-to-cover ratio is currently 6.1 days. View ACADIA Pharmaceuticals' Short Interest .

When is ACADIA Pharmaceuticals' next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Monday, May 13th 2024. View our ACAD earnings forecast .

How were ACADIA Pharmaceuticals' earnings last quarter?

ACADIA Pharmaceuticals Inc. (NASDAQ:ACAD) posted its quarterly earnings results on Tuesday, February, 27th. The biopharmaceutical company reported $0.28 earnings per share for the quarter, missing the consensus estimate of $0.32 by $0.04. The biopharmaceutical company had revenue of $231.04 million for the quarter, compared to analyst estimates of $223.79 million. ACADIA Pharmaceuticals had a negative net margin of 8.44% and a negative trailing twelve-month return on equity of 15.67%. The firm's revenue for the quarter was up 69.3% on a year-over-year basis. During the same period in the prior year, the company posted ($0.26) EPS.

What ETFs hold ACADIA Pharmaceuticals' stock?

ETFs with the largest weight of ACADIA Pharmaceuticals (NASDAQ:ACAD) stock in their portfolio include iShares Neuroscience and Healthcare ETF (IBRN) , First Trust NYSE Arca Biotechnology Index Fund (FBT) , Invesco Biotechnology & Genome ETF (PBE) , ALPS Medical Breakthroughs ETF (SBIO) , Virtus LifeSci Biotech Products ETF (BBP) , Principal Healthcare Innovators ETF (BTEC) , First Trust Nasdaq Pharmaceuticals ETF (FTXH) and iShares Biotechnology ETF (IBB) .

What guidance has ACADIA Pharmaceuticals issued on next quarter's earnings?

ACADIA Pharmaceuticals updated its FY 2024 earnings guidance on Tuesday, February, 27th. The company provided earnings per share (EPS) guidance of for the period. The company issued revenue guidance of $930.0 million-$1.0 billion, compared to the consensus revenue estimate of $965.1 million.

What is Steve Davis' approval rating as ACADIA Pharmaceuticals' CEO?

8 employees have rated ACADIA Pharmaceuticals Chief Executive Officer Steve Davis on Glassdoor.com . Steve Davis has an approval rating of 88% among the company's employees.

What other stocks do shareholders of ACADIA Pharmaceuticals own?

Based on aggregate information from My MarketBeat watchlists, some companies that other ACADIA Pharmaceuticals investors own include Micron Technology (MU) , NVIDIA (NVDA) , Gilead Sciences (GILD) , Sarepta Therapeutics (SRPT) , Pfizer (PFE) , Tesla (TSLA) , Alibaba Group (BABA) , Amarin (AMRN) , Advanced Micro Devices (AMD) and Exelixis (EXEL) .

Who are ACADIA Pharmaceuticals' major shareholders?

ACADIA Pharmaceuticals' stock is owned by many different institutional and retail investors. Top institutional shareholders include Hennion & Walsh Asset Management Inc. (0.09%), Los Angeles Capital Management LLC (0.04%), Allspring Global Investments Holdings LLC (0.04%) and Diversified Trust Co (0.02%). Insiders that own company stock include Austin D Kim, Austin D Kim , Brendan Teehan , Bros Advisors Lp Baker, Elena Ridloff , James Kihara , Laura Brege , Mark C Schneyer , Srdjan R Stankovic, Srdjan R Stankovic and Stephen Davis . View institutional ownership trends .

How do I buy shares of ACADIA Pharmaceuticals?

Shares of ACAD stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Compare Top Brokerages Here .

Most-Downgraded StocksMost-Downgraded

NASDAQ:ACAD

ACADIA Pharmaceuticals (ACAD) Stock Price, News & Analysis

→ I’m officially sounding the alarm. (From Altimetry) (Ad)

Free ACAD Stock Alerts

$17.07

-0.12 (-0.70%)

(As of 04/18/2024 ET)

Compare

Today's Range: $17.01
▼
$17.35
50-Day Range: $16.89
▼
$26.76
52-Week Range: $16.60
▼
$33.99

Volume: 988,316 shs
Average Volume: 1.33 million shs
Market Capitalization: $2.81 billion

P/E Ratio: N/A
Dividend Yield: N/A
Price Target: $35.82

Get ACADIA Pharmaceuticals alerts:

ACADIA Pharmaceuticals MarketRank™ Stock Analysis

Analyst Rating: Moderate Buy
2.80 Rating Score
Upside/Downside: 109.9% Upside
$35.82 Price Target
Short Interest: Bearish
6.80% of Shares Sold Short
Dividend Strength: N/A
Sustainability: N/A
News Sentiment: -0.18
Based on 11 Articles This Week
Insider Trading: Selling Shares
$1.29 M Sold Last Quarter
Proj. Earnings Growth: 88.89%
From $0.63 to $1.19 Per Share

Overall MarketRank^™

New Rank-Based ScoringMarketRank^™ is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.

3.48 out of 5 stars

Medical Sector

243rd out of 918 stocks

Pharmaceutical Preparations Industry

101st out of 429 stocks

4.4

Analyst's Opinion

Consensus Rating
ACADIA Pharmaceuticals has received a consensus rating of Moderate Buy. The company's average rating score is 2.80, and is based on 12 buy ratings, 3 hold ratings, and no sell ratings.
Amount of Analyst Coverage
ACADIA Pharmaceuticals has been the subject of 10 research reports in the past 90 days, demonstrating strong analyst interest in this stock.

1.0

Short Interest

Percentage of Shares Shorted
6.80% of the outstanding shares of ACADIA Pharmaceuticals have been sold short.
Short Interest Ratio / Days to Cover
ACADIA Pharmaceuticals has a short interest ratio ("days to cover") of 6.1.
Change versus previous month
Short interest in ACADIA Pharmaceuticals has recently increased by 5.36%, indicating that investor sentiment is decreasing significantly.

0.0

Dividend Strength

Dividend Yield
ACADIA Pharmaceuticals does not currently pay a dividend.
Dividend Growth
ACADIA Pharmaceuticals does not have a long track record of dividend growth.

N/A

Sustainability and ESG

Overall ESG (Environmental, Social, and Governance) Score
There is no current Upright™ data available for ACAD.

1.0

News and Social Media Coverage

News Sentiment
ACADIA Pharmaceuticals has a news sentiment score of -0.18. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.53 average news sentiment score of Medical companies.
News Coverage This Week
MarketBeat has tracked 11 news articles for ACADIA Pharmaceuticals this week, compared to 6 articles on an average week.
Search Interest
Only 13 people have searched for ACAD on MarketBeat in the last 30 days. This is a decrease of -38% compared to the previous 30 days.
MarketBeat Follows
Only 10 people have added ACADIA Pharmaceuticals to their MarketBeat watchlist in the last 30 days. This is a decrease of -17% compared to the previous 30 days.

4.2

Company Ownership

Insider Buying vs. Insider Selling
In the past three months, ACADIA Pharmaceuticals insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $1,291,362.00 in company stock.
Percentage Held by Insiders
27.50% of the stock of ACADIA Pharmaceuticals is held by insiders. A high percentage of insider ownership can be a sign of company health.
Percentage Held by Institutions
96.71% of the stock of ACADIA Pharmaceuticals is held by institutions. High institutional ownership can be a signal of strong market trust in this company.

1.9

Earnings and Valuation

Earnings Growth
Earnings for ACADIA Pharmaceuticals are expected to grow by 88.89% in the coming year, from $0.63 to $1.19 per share.
Price to Earnings Ratio vs. the Market
The P/E ratio of ACADIA Pharmaceuticals is -44.92, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.
Price to Earnings Ratio vs. Sector
The P/E ratio of ACADIA Pharmaceuticals is -44.92, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.
Price to Book Value per Share Ratio
ACADIA Pharmaceuticals has a P/B Ratio of 6.49. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities.

See Top Rated MarketRank™ Stocks Here

Ad Gold Safe Exchange

The “Perfect Storm” for Gold

Gold has already reached all-time highs, and experts believe it's not slowing down any time soon. In fact, some analysts predict a $7,000 price tag by 2025.

Click here now to download the free Precious Metals Buying Guide!

About ACADIA Pharmaceuticals Stock (NASDAQ:ACAD)

ACADIA Pharmaceuticals Inc., a biopharmaceutical company, focuses on the development and commercialization innovative medicines that address unmet medical needs in central nervous system (CNS) disorders and rare diseases in the United States. The company offers NUPLAZID (pimavanserin) for the treatment of hallucinations and delusions associated with Parkinson's disease psychosis; and DAYBUE, a novel synthetic analog of the amino-terminal tripeptide of insulin-like growth factor 1 for treatment of Rett Syndrome. It also develops Pimavanserin that is in Phase III ADVANCE-2 study to treat the negative symptoms of schizophrenia; ACP-101 whixh is in Phase III for the treatment of hyperphagia in Prader-Willi syndrome; ACP-204 which is in Phase II for the treatment of Alzheimer's disease psychosis; ACP-2591 that is in Phase I for Rett syndrome and Fragile X syndrome; preclinical antisense oligonucleotide programs; and other programs for neuropsychiatric symptoms. It has a license agreement with Neuren Pharmaceuticals Limited to develop and commercialize trofinetide for Rett syndrome and other indications; and a license and collaboration agreement with Stoke Therapeutics, Inc. to discover, develop and commercialize novel RNA-based medicines for the potential treatment of severe and rare genetic neurodevelopmental diseases of the CNS. The company was formerly known as Receptor Technologies, Inc. and changed its name ACADIA Pharmaceuticals Inc. in 1997. ACADIA Pharmaceuticals Inc. was incorporated in 1993 and is headquartered in San Diego, California.

ACAD Stock Price History

30 days | 90 days | 365 days | Advanced Chart

ACAD Stock News Headlines

April 10, 2024 | insidertrades.com

ACADIA Pharmaceuticals Inc. (NASDAQ:ACAD) Insider James Kihara Sells 1,790 Shares

March 29, 2024 | insidertrades.com

Insider Selling: ACADIA Pharmaceuticals Inc. (NASDAQ:ACAD) COO Sells 5,140 Shares of Stock

April 19, 2024 | Altimetry (Ad)

I’m officially sounding the alarm.

AI has been the hottest financial story of 2023. And rightly so – AI stocks have beat the broader market by over 62%. But right now, my system is warning me that many AI stocks are riding higher on hype alone.

April 18, 2024 | americanbankingnews.com

ACADIA Pharmaceuticals (NASDAQ:ACAD) Reaches New 52-Week Low at $16.60

April 17, 2024 | businesswire.com

Acadia Pharmaceuticals Presents New DAYBUE™ (trofinetide) Clinical Data at the 2024 American Academy of Neurology (AAN) Annual Meeting

April 16, 2024 | americanbankingnews.com

ACADIA Pharmaceuticals Inc. (NASDAQ:ACAD) Short Interest Up 5.4% in March

April 15, 2024 | markets.businessinsider.com

Analysts Offer Insights on Healthcare Companies: 4D Molecular Therapeutics (FDMT), Acadia Healthcare (ACHC) and Coherus Biosciences (CHRS)

April 13, 2024 | americanbankingnews.com

Brokers Issue Forecasts for ACADIA Pharmaceuticals Inc.'s FY2026 Earnings (NASDAQ:ACAD)

April 19, 2024 | Altimetry (Ad)

I’m officially sounding the alarm.

April 12, 2024 | stocknews.com

3 Affordable Pharma Stocks to Buy for Portfolio Gains

April 12, 2024 | americanbankingnews.com

Leerink Partnrs Analysts Cut Earnings Estimates for ACADIA Pharmaceuticals Inc. (NASDAQ:ACAD)

April 11, 2024 | investing.com

Acadia Pharmaceuticals executive sells over $31,000 in company stock

April 11, 2024 | investing.com

Acadia Pharmaceuticals exec sells over $45k in stock

April 11, 2024 | investorplace.com

3 Pharma Stocks to Sell in April Before They Crash & Burn

April 11, 2024 | markets.businessinsider.com

Buy Rating Justified by Vertex Pharmaceuticals’ Strategic Acquisitions and Promising Drug Pipeline

April 11, 2024 | americanbankingnews.com

ACADIA Pharmaceuticals' (ACAD) Overweight Rating Reiterated at Cantor Fitzgerald

April 11, 2024 | americanbankingnews.com

ACADIA Pharmaceuticals (NASDAQ:ACAD) Sets New 12-Month Low Following Insider Selling

April 10, 2024 | markets.businessinsider.com

Cracking The Code: Understanding Analyst Reviews For ACADIA Pharmaceuticals

April 10, 2024 | americanbankingnews.com

ACADIA Pharmaceuticals Inc. (NASDAQ:ACAD) CFO Mark C. Schneyer Sells 2,716 Shares

April 10, 2024 | americanbankingnews.com

ACADIA Pharmaceuticals Inc. (NASDAQ:ACAD) COO Brendan Teehan Sells 2,568 Shares

April 10, 2024 | americanbankingnews.com

ACADIA Pharmaceuticals Inc. (NASDAQ:ACAD) CEO Stephen Davis Sells 26,574 Shares

April 10, 2024 | americanbankingnews.com

ACADIA Pharmaceuticals (NASDAQ:ACAD) Receives Buy Rating from Needham & Company LLC

April 9, 2024 | markets.businessinsider.com

Analysts Are Bullish on Top Healthcare Stocks: Harmony Biosciences Holdings (HRMY), Recursion Pharmaceuticals (RXRX)

April 4, 2024 | investing.com

Acadia Pharmaceuticals names new EVP of Research and Development

April 1, 2024 | finance.yahoo.com

Acadia Pharmaceuticals to Participate in the 23rd Annual Needham Virtual Healthcare Conference

April 1, 2024 | markets.businessinsider.com

Buy Rating Affirmed for Syros Pharmaceuticals Amid Promising Clinical Trials and Strategic Study Designs

March 28, 2024 | uk.investing.com

These Overlooked Mid-Cap Gems Are Ripe for a Rebound

See More Headlines

Receive ACAD Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for ACADIA Pharmaceuticals and its competitors with MarketBeat's FREE daily newsletter.

Company Calendar

Last Earnings: 2/27/2024
Today: 4/19/2024
Next Earnings (Estimated): 5/13/2024
Fiscal Year End: 12/31/2024

Get Stock Alerts

Industry, Sector and Symbol

Stock Exchange: NASDAQ
Sector: Medical
Industry: Pharmaceutical preparations
Sub-Industry: N/A
Current Symbol: NASDAQ:ACAD
CUSIP: N/A
CIK: 1070494
Web: www.acadia-pharm.com
Phone: (858) 558-2871
Fax: 858-558-2872
Employees: 597
Year Founded: N/A

Price Target and Rating

Average Stock Price Target: $35.82
High Stock Price Target: $95.00
Low Stock Price Target: $25.00
Potential Upside/Downside: +109.9%
Consensus Rating: Moderate Buy
Rating Score (0-4): 2.80
Research Coverage: 15 Analysts

Profitability

EPS (Most Recent Fiscal Year): ($0.38)
Trailing P/E Ratio: N/A
Forward P/E Ratio: 27.10
P/E Growth: N/A
Net Income: $-61,290,000.00
Net Margins: -8.44%
Pretax Margin: -7.03%
Return on Equity: -15.67%
Return on Assets: -9.15%

Debt

Debt-to-Equity Ratio: N/A
Current Ratio: 2.42
Quick Ratio: 2.28

Sales & Book Value

Annual Sales: $726.44 million
Price / Sales: 3.87
Cash Flow: N/A
Price / Cash Flow: N/A
Book Value: $2.63 per share
Price / Book: 6.49

Miscellaneous

Outstanding Shares: 164,770,000
Free Float: 119,460,000
Market Cap: $2.81 billion
Optionable: Optionable
Beta: 0.37

Investing Strategies To Help Grow Your Retirement Income

Need to stretch out your 401K or Roth IRA plan? Use these time-tested investing strategies to grow the monthly retirement income that your stock portfolio generates.

Get This Free Report

Key Executives

Mr. Stephen R. Davis J.D. (Age 63)
President, CEO & Director
Comp: $1.46M
Mr. Mark C. Schneyer (Age 49)
Executive VP & CFO
Comp: $701.03k
Mr. Brendan P. Teehan (Age 55)
Executive VP, COO & Head of Commercial
Comp: $724.31k
Mr. James K. Kihara (Age 43)
VP, Chief Accounting Officer & Corporate Controller
Mr. Benir Ruano
Senior Vice President of Technical Development & Operations
Mr. Albert S. Kildani
Senior Vice President of Investor Relations & Corporate Communications
Ms. Jennifer J. Rhodes J.D. (Age 54)
Executive VP, Chief Legal Officer & Secretary
Ms. Julie Fisher
Senior Vice President of Marketing & Commercial Strategy
Ms. Holly Valdiviez
Senior VP & Head of Sales
Mr. Rob Ackles
Senior VP & Chief People Officer

Key Competitors

View All Competitors

Insiders & Institutions

View All Insider Transactions
View All Institutional Transactions

ACAD Stock Analysis - Frequently Asked Questions

Should I buy or sell ACADIA Pharmaceuticals stock right now?: 15 Wall Street analysts have issued "buy," "hold," and "sell" ratings for ACADIA Pharmaceuticals in the last twelve months. There are currently 3 hold ratings and 12 buy ratings for the stock. The consensus among Wall Street analysts is that investors should "moderate buy" ACAD shares.
View ACAD analyst ratings or view top-rated stocks.
What is ACADIA Pharmaceuticals' stock price target for 2024?: 15 Wall Street analysts have issued 1 year target prices for ACADIA Pharmaceuticals' stock. Their ACAD share price targets range from $25.00 to $95.00. On average, they anticipate the company's share price to reach $35.82 in the next twelve months. This suggests a possible upside of 109.9% from the stock's current price.
View analysts price targets for ACAD or view top-rated stocks among Wall Street analysts.
How have ACAD shares performed in 2024?: ACADIA Pharmaceuticals' stock was trading at $31.31 at the beginning of 2024. Since then, ACAD stock has decreased by 45.5% and is now trading at $17.07.
View the best growth stocks for 2024 here.
Are investors shorting ACADIA Pharmaceuticals?: ACADIA Pharmaceuticals saw a increase in short interest in March. As of March 31st, there was short interest totaling 11,200,000 shares, an increase of 5.4% from the March 15th total of 10,630,000 shares. Based on an average daily volume of 1,830,000 shares, the days-to-cover ratio is currently 6.1 days.
View ACADIA Pharmaceuticals' Short Interest.
When is ACADIA Pharmaceuticals' next earnings date?: The company is scheduled to release its next quarterly earnings announcement on Monday, May 13th 2024.
View our ACAD earnings forecast.
How were ACADIA Pharmaceuticals' earnings last quarter?: ACADIA Pharmaceuticals Inc. (NASDAQ:ACAD) posted its quarterly earnings results on Tuesday, February, 27th. The biopharmaceutical company reported $0.28 earnings per share for the quarter, missing the consensus estimate of $0.32 by $0.04. The biopharmaceutical company had revenue of $231.04 million for the quarter, compared to analyst estimates of $223.79 million. ACADIA Pharmaceuticals had a negative net margin of 8.44% and a negative trailing twelve-month return on equity of 15.67%. The firm's revenue for the quarter was up 69.3% on a year-over-year basis. During the same period in the prior year, the company posted ($0.26) EPS.

What ETFs hold ACADIA Pharmaceuticals' stock?: ETFs with the largest weight of ACADIA Pharmaceuticals (NASDAQ:ACAD) stock in their portfolio include iShares Neuroscience and Healthcare ETF (IBRN), First Trust NYSE Arca Biotechnology Index Fund (FBT), Invesco Biotechnology & Genome ETF (PBE), ALPS Medical Breakthroughs ETF (SBIO), Virtus LifeSci Biotech Products ETF (BBP), Principal Healthcare Innovators ETF (BTEC), First Trust Nasdaq Pharmaceuticals ETF (FTXH) and iShares Biotechnology ETF (IBB).
What guidance has ACADIA Pharmaceuticals issued on next quarter's earnings?: ACADIA Pharmaceuticals updated its FY 2024 earnings guidance on Tuesday, February, 27th. The company provided earnings per share (EPS) guidance of for the period. The company issued revenue guidance of $930.0 million-$1.0 billion, compared to the consensus revenue estimate of $965.1 million.
What is Steve Davis' approval rating as ACADIA Pharmaceuticals' CEO?: 8 employees have rated ACADIA Pharmaceuticals Chief Executive Officer Steve Davis on Glassdoor.com. Steve Davis has an approval rating of 88% among the company's employees.
What other stocks do shareholders of ACADIA Pharmaceuticals own?: Based on aggregate information from My MarketBeat watchlists, some companies that other ACADIA Pharmaceuticals investors own include Micron Technology (MU), NVIDIA (NVDA), Gilead Sciences (GILD), Sarepta Therapeutics (SRPT), Pfizer (PFE), Tesla (TSLA), Alibaba Group (BABA), Amarin (AMRN), Advanced Micro Devices (AMD) and Exelixis (EXEL).
Who are ACADIA Pharmaceuticals' major shareholders?: ACADIA Pharmaceuticals' stock is owned by many different institutional and retail investors. Top institutional shareholders include Hennion & Walsh Asset Management Inc. (0.09%), Los Angeles Capital Management LLC (0.04%), Allspring Global Investments Holdings LLC (0.04%) and Diversified Trust Co (0.02%). Insiders that own company stock include Austin D Kim, Austin D Kim, Brendan Teehan, Bros Advisors Lp Baker, Elena Ridloff, James Kihara, Laura Brege, Mark C Schneyer, Srdjan R Stankovic, Srdjan R Stankovic and Stephen Davis.
View institutional ownership trends.
How do I buy shares of ACADIA Pharmaceuticals?: Shares of ACAD stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.
Compare Top Brokerages Here.

This page (NASDAQ:ACAD) was last updated on 4/19/2024 by MarketBeat.com Staff

From Our Partners

Get 30 Days of MarketBeat All Access Free

Best-in-Class Portfolio Monitoring
View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio.
Stock Ideas and Recommendations
Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report.
Advanced Stock Screeners and Research Tools
Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis.

Start Your 30-Day Free Trial

ACADIA Pharmaceuticals (ACAD) Stock Price, News & Analysis

ACADIA Pharmaceuticals MarketRank™ Stock Analysis

Overall MarketRank™

Analyst's Opinion

Short Interest

Percentage of Shares Shorted

Short Interest Ratio / Days to Cover

Change versus previous month

Dividend Strength

Sustainability and ESG

Overall ESG (Environmental, Social, and Governance) Score

News and Social Media Coverage

News Sentiment

News Coverage This Week

Search Interest

MarketBeat Follows

Company Ownership

Earnings and Valuation

About ACADIA Pharmaceuticals Stock (NASDAQ:ACAD)

ACAD Stock Price History

ACAD Stock News Headlines

Company Calendar

Industry, Sector and Symbol

Price Target and Rating

Profitability

Debt

Sales & Book Value

Miscellaneous

Key Executives

Key Competitors

Insiders & Institutions

ACAD Stock Analysis - Frequently Asked Questions

Overall MarketRank^™